Today’s upgrades for Validea’s Earnings Yield Investor model include HARMONY BIOSCIENCES HOLDINGS INC (HRMY), a small-cap value stock in the Biotechnology & Drugs industry. The rating based on Joel Greenblatt’s strategy changed from 80% to 90% due to the firm’s strong fundamentals and stock valuation.

Harmony Biosciences Holdings, Inc. focuses on developing and commercializing therapies for rare neurological diseases. Their product, WAKIX, is designed to treat excessive daytime sleepiness in pediatric patients with narcolepsy. The company also has an investigational compound and drug product in development for other neurological conditions. The stock meets the criteria for the strategy’s tests, with a neutral earnings yield and return on tangible capital, resulting in a passing final ranking.

Read more at Nasdaq: Validea Joel Greenblatt Strategy Daily Upgrade Report – 9/25/2025